Roche Holding | ROG - Gross Profit On Sales


Roche Holding reported CHF22.69B in Gross Profit on Sales for its fiscal semester ending in June of 2026.





Gross Profit On Sales Change Date
AbbVie USD 14.39B 1.85B Jun/2026
Alcon AG USD 1.69B 175M Mar/2026
Almirall EUR 429.87M 180.02M Dec/2025
Amgen USD 5.87B 1.02B Mar/2026
AstraZeneca USD 12.86B 251M Jun/2026
Bayer EUR 8.17B 1.24B Mar/2026
Biogen USD 2.12B 307M Jun/2026
Bristol-Myers Squibb USD 9.26B 1.19B Jun/2026
Eli Lilly USD 16.22B 301.7M Mar/2026
Fresenius EUR 1.55B 16M Jun/2026
Fresenius Medical Care EUR 1.18B 210M Mar/2026
Genmab DKK 1.07B 240M Jun/2026
Gilead Sciences USD 6.8B 1.29B Jun/2026
GlaxoSmithKline GBP 6.51B 757M Jun/2026
GRIFOLS EUR 704M 84M Jun/2026
Hikma Pharmaceutical USD 362.5M 329.5M Jun/2025
Lakefront Biotherapeutics EUR 1.68M 898.68M Mar/2026
Lonza CHF 1.29B 248M Jun/2025
Merck EUR 3.07B 104M Mar/2026
Merck USD 12.09B 1.24B Mar/2026
Novartis USD 11.24B 1.18B Jun/2026
Orion EUR 339.9M 85.9M Jun/2026
Pfizer USD -248M 11.29B Jun/2026
Philips EUR 2.15B 384M Jun/2026
Recordati EUR 497.97M 12.85M Jun/2026
Regeneron Pharmaceuticals USD 3.71B 778.2M Jun/2026
Roche Holding CHF 22.69B 600M Jun/2026
Sanofi EUR 8.71B 602M Jun/2026
UCB EUR 3.19B 621M Dec/2025